Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

New England Journal of Medicine

Volumn 370, Issue 22, 2014, Pages 2071-2082

  Richeldi, Luca ^a   Du Bois, Roland M ^b   Raghu, Ganesh ^d   Azuma, Arata ^e   Brown, Kevin K ^h   Costabel, Ulrich ⁱ   Cottin, Vincent ^k   Flaherty, Kevin R ^m   Hansell, David M ^c   Inoue, Yoshikazu ^f   Kim, Dong Soon ⁿ   Kolb, Martin ^o   Nicholson, Andrew G ^c   Noble, Paul W ^p   Selman, Moisés ^q   Taniguchi, Hiroyuki ^g   Brun, Michèle ^l   Le Maulf, Florence ^l   Girard, Mannaïg ^l   Stowasser, Susanne ^j   Schlenker Herceg, Rozsa ^r   Disse, Bernd ^j   Collard, Harold R ^s   more..

^a University Hospital Southampton NHS Foundation Trust   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF WASHINGTON   (United States)

^e NIPPON MEDICAL SCHOOL   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^g TOSEI GENERAL HOSPITAL   (Japan)

^h DEPARTMENT OF MEDICINE   (United States)

ⁱ RUHRLANDKLINIK   (Germany)

^j BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^k UNIVERSITÉ DE LYON   (France)

^l BOEHRINGER INGELHEIM   (France)

^m UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

ⁿ University of Ulsan   (South Korea)

^o MCMASTER UNIVERSITY   (Canada)

^p CEDARS SINAI MEDICAL CENTER   (United States)

^q INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^r BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^s UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; NINTEDANIB; PLACEBO;

AGED; ARTICLE; CONTROLLED STUDY; DEATH; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HEART INFARCTION; HUMAN; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST. GEORGE RESPIRATORY QUESTIONNAIRE;

AGED; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUALITY OF LIFE; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84901810710     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1402584     Document Type: Article

References (20)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement - idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
2. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011;184:1382-9.
3. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-42. (Pubitemid 37088595)
4. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-8. (Pubitemid 37088596)
5. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-7. (Pubitemid 37088594)
6. King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005;127:171-7. (Pubitemid 41724573)
7. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378:1949-61.
8. Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007;29:976-85. (Pubitemid 46711904)
9. Coward WR, Saini G, Jenkins G. The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2010;4:367-88.
10. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Anti-fibrotic and antiinflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014;349:209-20.
11. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-82.
12. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-87.
13. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38. (Pubitemid 41079078)
14. Jones PW, Quirk FH, Baveystock CM. The St. George's Respiratory Questionnaire. Respir Med 1991;85:Suppl B:25-31.
15. Barr JT, Schumacher GE, Freeman S, LeMoine M, Bakst AW, Jones PW. American translation, modification, and validation of the St. George's Respiratory Questionnaire. Clin Ther 2000;22:1121-45.
16. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005;2:75-9.
17. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-43. (Pubitemid 47503070)
18. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC. Standardization of the measurement of transfer factor (diffusing capacity). Report of the Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:41-52.
19. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011;37:356-63.
20. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res 2013;14:73.